MedTrace Logo

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

NCT03700320 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 744

Last updated 2021-06-15

Study results available
· View outcomes & findings →

Summary

This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.

Conditions

  • Episodic Migraine

Interventions

DRUG

Standard of Care (SOC) Migraine Preventive Medication

Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.

DRUG

Atogepant

Atogepant tablets taken orally, once daily for 52 weeks.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Joel Trugman, MD · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2020-05-21
Completion
2020-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03700320 on ClinicalTrials.gov